small ruminants
  • Blog
  • Videos
  • About us
  • Contact us
  • Subscribe
  • English
    • Français
    • Italiano
    • Español
    • Ελληνικα
  • Blog
  • Videos
  • About us
  • Contact us
  • Subscribe
  • English
    • Français
    • Italiano
    • Español
    • Ελληνικα

Reduction of staphylococcal shedding by vaccination against mastitis in sheep and goats

  • July 1, 2021
Facebook
Twitter
LinkedIn
Mastitis in sheep and goats caused by staphylococci is very well known in the sector. The reduction of shedding is key to controlling this common problem on farms. The infection very often spreads within the milking parlour. In Greece, two experimental studies were performed to determine the effect of vaccination on the reduction of shedding, by taking samples from the teatcups… A peer-reviewed article of this work has now been published. To find out more…don’t miss this post! 

 

Staphyloccoci…the cause of a serious problem!

Amongst all the problems that we can find on farms, mastitis in sheep and goats is normally the one that farmers and vets are most concerned about, for two main reasons: its economic impact and the difficulty in controlling it.

There is a high risk of transmission of staphylococci during milking, thus leading to intramammary infection.

Staphyloccocus aureus and CNS are the most prevalent pathogens causing both clinical and subclinical mastitis cases.

“Staph aureus and CNS, the main causes of clinical and subclinical mastitis”

A group of scientists performed two field investigations throughout Greece to associate the staphylococcal populations with the use of anti-staphylococcal mastitis vaccines.

 

How was it done?

Samples were taken from the teatcups (upper and lower part) to confirm the shedding of staphylococci.

A total of 1418 samples were collected from 333 farms (255 sheep and 66 goat farms respectively) that were involved in the cross-sectional study.

 

What was isolated?

The results of these studies confirmed that these staphylococci are very often circulating on small ruminant farms, becoming a great threat to the sector.

 

Proportion of contaminated teatcups

Figure 1: On vaccinated farms, fewer contaminated teatcups (S.aureus and CNS) were found in comparison to unvaccinated farms; these results suggest that vaccination against mastitis in sheep and goats helps to reduce the shedding of staphylococci and consequently, the spread of the infection.

Of the total number of samples collected, 23% were infected; the presence of staphylococci was confirmed on 41.2% of the sheep farms; and it was even higher for the goat herds, 53%.

“Staphylococci were found on over 50% of dairy goat farms”

Different staphylococcal species were isolated but the majority were biofilm-forming staph, 87.4%; there was no difference in isolates from sheep and goat farms in the study.

“Over 87% of staphylococcal species isolated were the biofilm-forming type”

Biofilm-forming strains of staphylococci are more resistant to antibiotic treatment and immune system cells, which helps the bacteria to attach on to the teatcups and survive the unfavourable conditions.

 

Different types of vaccines…different impact!

In the cross-sectional study, three commercial vaccines were used on some farms (42%); fewer contaminated teatcups were found on vaccinated farms in both studies.

 

Effect of vaccination in the proportion of contaminated teatcups

Figure 2: Proportion of contaminated teatcups found on farms: unvaccinated, vaccine I (Mastivet), vaccine II (Ovax), vaccine III (VIMCO & Startvac) and vaccine IV (autogenous); farms vaccinated with VIMCO & Startvac resulted in a smaller proportion of contaminated (staphylococci) teatcups. This suggests that these vaccines against mastitis in sheep and goats significantly reduce shedding, helping to control the spread of the infection in the flock/herd.

These results suggest that vaccination against mastitis reduces shedding, which is crucial to the control of mastitis on sheep and goat farms.

“Farms vaccinated with VIMCO® or STARTVAC®: biofilm-forming staphylococci isolated in only 10.9% of teatcups”

Farms on which vaccine against antibiofilm-forming was used, showed a greater reduction in contaminated teatcups than farms where other commercial vaccines were used or unvaccinated farms: 12.1% vs 25.1%.

 

Conclusions

● The majority of staphyloccoci isolates were biofilm-forming staphylococci.  
● Anti-staphylococcal mastitis vaccination reduces the spread on farms.
● VIMCO® and STARTVAC® showed a higher reduction of shedding than other mastitis vaccines.


ACCESS TO THE PEER REVIEWED ARTICLE

 

 

Authors of the study:

Charalambia K. Michael, Daphne T. Lianou, Natalia G.C. Vasileiou, Katerina Tsilipounidaki, Angeliki I. Katsafadou, Antonis P. Politis, Nikos G. Kordalis, Katerina S. Ioannidi, Dimitris A. Gougoulis, Constantina Trikalinou, Denise C. Orfanou, Ilektra A. Fragkou, Panagiota I. Kontou, Dimitra V. Liagka, Vasia S. Mavrogianni, Efthimia Petinaki and George C. Fthenakis.  
Previous Post

Evaluation of the efficacy of the latest inactivated vaccine against enzootic abortion

Next Post

History of antibiotics: the battle between humans and bacteria

Related Posts

How can we calculate the profitability of vaccination against abortions?

Key points for the diagnosis of 𝘊. 𝘢𝘣𝘰𝘳𝘵𝘶𝘴: act quickly to effectively control it

October 21, 2025

Transmission of pathogens during milking is the main cause of mastitis in small ruminants. Improper use or malfunction of milking...

Impact Of Vaccination Against Mastitis In Primiparous Goats: A Study In The Netherlands

Beyond health: the economic impact of resistance

September 14, 2025

Transmission of pathogens during milking is the main cause of mastitis in small ruminants. Improper use or malfunction of milking...

CATEGORIES

  • Antibiotic reduction
  • Field experience
  • Footrot
  • Mastitis
  • Other Goats, Sheep and Lamb Diseases
  • Reproductive
  • Respiratory

NEWSLETTER

DON’T MISS ANY UPDATES ON SMALL RUMINANTS

    I have read and agree to the Privacy Policy and Basic information on Data Protection.

    ASK THE EXPERTS

    Your opinion is very important to us, so we encourage you to contact our team of experts on Small Ruminants to ask any questions or discuss any concerns you may have about sheep, goats and lambs health prevention.

      I have read and agree to the Privacy Policy and Basic information on Data Protection.

      Next Post
      History of antibiotics: the battle between humans and bacteria

      History of antibiotics: the battle between humans and bacteria

      small ruminants

      Follow us

      Linkedin Youtube
      Categories
      • Antibiotic reduction
      • Field experience
      • Footrot
      • Mastitis
      • Other Goats, Sheep and Lamb Diseases
      • Reproductive
      • Respiratory

      Pages

      • Blog
      • Videos
      • About us
      • Contact

      HIPRA ©2025 All rights reserved

      • Cookie policy
      • Terms of use
      • Privacy policy
      • Cookie policy
      • Terms of use
      • Privacy policy

      Mastitis control program

      Our 6-point mastitis control program is a set of structured measures and practices, validated to improve udder health and milk quality in dairy farms.



        Basic Personal Data Protection information:

        Controller: LABORATORIOS HIPRA, S.A.
        Purposes: Managing the contractual and/or business relationship with HIPRA, including sending news, promotions and invitations to events sponsored by HIPRA.
        Lawful basis: Performance of the contractual relationship and HIPRA's legitimate Interest.
        Recipients: Third parties to which HIPRA has entrusted cloud computing, security, auditing, mailing, technical and computer support services, as well as companies in its group.
        Rights: Request access to and rectification or erasure of personal data and other rights as explained in the additional information. You can seeview the detailed additional information about data protection in our
        Privacy Policy.

        For further information, please check our detailed information on Data Protection.
        close-link
        Powered by Convert Plus

        Basic Personal Data Protection information:

        Controller: LABORATORIOS HIPRA, S.A.
        Purposes: Managing the contractual and/or business relationship with HIPRA, including sending news, promotions and invitations to events sponsored by HIPRA.
        Lawful basis: Performance of the contractual relationship and HIPRA’s legitimate Interest.
        Recipients: Third parties to which HIPRA has entrusted cloud computing, security, auditing, mailing, technical and computer support services, as well as companies in its group.
        Rights: Request access to and rectification or erasure of personal data and other rights as explained in the additional information. You can seeview the detailed additional information about data protection in our Privacy Policy.

        For further information, please check our detailed information on Data Protection.

        Website for veterinarians

        The contents of this website are aimed exclusively at prescribing veterinarians. By clicking on Accept you state that you are a veterinary professional. In other case, please contact a veterinarian and click on Decline.

        ACCEPT
        DECLINE

        NEWSLETTER

        Don´t miss any updates

          I have read and agree to the Privacy Policy and Basic information on Data Protection.

          Informazioni di base sulla protezione dei dati personali:

          Titolare del trattamento: LABORATORIOS HIPRA, S.A.
          Finalità: Gestione del rapporto contrattuale e/o commerciale con HIPRA, incluso l’invio di notizie, promozioni e inviti a eventi sponsorizzati da HIPRA.
          Base giuridica: Esecuzione del rapporto contrattuale e del legittimo interesse di HIPRA.
          Destinatari: Terzi a cui HIPRA ha affidato servizi di cloud computing, sicurezza, auditing, mailing, supporto tecnico e informatico, nonché società del suo gruppo.
          Diritti: Richiedere l'accesso e la rettifica o la cancellazione dei dati personali e altri diritti come spiegato nelle informazioni aggiuntive. Puoi vedere le informazioni aggiuntive dettagliate sulla protezione dei dati nella nostra Informativa sulla privacy.

          Per ulteriori informazioni, puoi consultare le nostre informazioni dettagliate sulla Protezione dei dati.

          Informations de base sur la protection des données personnelles :

          Contrôleur : LABORATORIOS HIPRA, S.A.
          Objectifs : Gérer la relation contractuelle et/ou commerciale avec HIPRA, y compris l'envoi de nouvelles, de promotions et d'invitations à des événements sponsorisés par HIPRA.
          Base légale : Exécution de la relation contractuelle et intérêt légitime d'HIPRA.
          Destinataires : Tiers auxquels HIPRA a confié le cloud computing, la sécurité, l'audit, le mailing, les aspects techniques et informatiques services de support, ainsi que les sociétés de son groupe.
          Droits : demander l'accès et la rectification ou l'effacement des données personnelles et d'autres droits comme expliqué dans les informations supplémentaires. Vous pouvez consulter les informations supplémentaires détaillées sur la protection des données dans notre Politique de confidentialité.

          Pour plus d'informations, veuillez consulter nos informations détaillées sur la protection des données. .

          Βασικές πληροφορίες προστασίας προσωπικών δεδομένων:

          Ελεγκτής: ΕΡΓΑΣΤΗΡΙΟ HIPRA, S.A.
          Σκοποί: Διαχείριση της συμβατικής ή/και επιχειρηματικής σχέσης με την HIPRA, συμπεριλαμβανομένης της αποστολής ειδήσεων, προωθήσεων και προσκλήσεων σε εκδηλώσεις που χρηματοδοτούνται από την HIPRA.
          Νόμιμη βάση: Εκτέλεση της συμβατικής σχέσης και έννομο συμφέρον της HIPRA.
          Παραλήπτες: Τρίτα μέρη στα οποία η HIPRA έχει εμπιστευθεί το cloud computing, την ασφάλεια, τον έλεγχο, την αλληλογραφία, την τεχνική και τον υπολογιστή υπηρεσίες υποστήριξης, καθώς και εταιρείες του ομίλου της.
          Δικαιώματα: Ζητήστε πρόσβαση και διόρθωση ή διαγραφή προσωπικών δεδομένων και άλλων δικαιωμάτων, όπως εξηγείται στις πρόσθετες πληροφορίες. Μπορείτε να δείτε αναλυτικές πρόσθετες πληροφορίες σχετικά με την προστασία δεδομένων στο Πολιτική Απορρήτου.

          Για περισσότερες πληροφορίες, ελέγξτε τις λεπτομερείς πληροφορίες σχετικά με την Προστασία Δεδομένων .

          Información básica sobre protección de datos:

          Responsable del tratamiento: LABORATORIOS HIPRA, S.A.
          Propósitos: Gestionar la relación contractual y comercial con HIPRA, incluido el envío de noticias, promociones e invitaciones a eventos patrocinados por HIPRA.
          Fundamentos legales: Cumplimiento de la relación contractual e interés legítimo de HIPRA.
          Destinatarios: Terceros a los que HIPRA ha encargado las tareas de computación en la nube, seguridad, auditoría, correo, servicios de soporte técnico e informático, así como empresas de su grupo.
          Derechos: Solicitar el acceso y la rectificación o eliminación de los datos personales y otros derechos, tal como se explica en la información adicional. Puede ver la información adicional detallada sobre la protección de datos en nuestra Política de Privacidad.

          Para obtener más información, consulte nuestra información detallada sobre Protección de datos.

          Basic Personal Data Protection information:

          Controller: LABORATORIOS HIPRA, S.A.
          Purposes: Managing the contractual and/or business relationship with HIPRA, including sending news, promotions and invitations to events sponsored by HIPRA.
          Lawful basis: Performance of the contractual relationship and HIPRA's legitimate Interest.
          Recipients: Third parties to which HIPRA has entrusted cloud computing, security, auditing, mailing, technical and computer support services, as well as companies in its group.
          Rights: Request access to and rectification or erasure of personal data and other rights as explained in the additional information. You can seeview the detailed additional information about data protection in our Privacy Policy.

          For further information, please check our detailed information on Data Protection.